Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabozantinib S-Malate

FDA-approved product (capsule, oral), marketed as Cabometyx, Cabozantinib S-Malate, Cometriq.

Registered studies
45
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Cabozantinib S-Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Neoplasm
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabozantinib S-Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabozantinib S-Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

    NCT06811116 · start 2025-11-17

    Registered record
    Registry ID
    NCT06811116
    Conditions
    Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Imaging Procedure; Sapanisertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-11-17
    Completion
    2027-08-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8
    InterventionBiospecimen Collection; Cabozantinib S-malate; Imaging Procedure; Sapanisertib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

    NCT06006013 · start 2025-01-15

    Registered record
    Registry ID
    NCT06006013
    Conditions
    Locally Advanced Adrenal Cortex Carcinoma; Adrenal Cortical Carcinoma; Stage III Adrenal Cortex Carcinoma; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma
    Interventions
    Pembrolizumab; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2028-12-16
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Adrenal Cortex Carcinoma; Adrenal Cortical Carcinoma; Stage III Adrenal Cortex Carcinoma; Stage IV Adrenal Cortex Carcinoma AJCC v8 +1 more
    InterventionPembrolizumab; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

    NCT05904080 · start 2024-02-19

    Registered record
    Registry ID
    NCT05904080
    Conditions
    Metastatic Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2024-02-19
    Completion
    2028-06-16
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Stage IV Nasopharyngeal Carcinoma AJCC v8
    InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Ipilimumab +2 more
    PhasePhase 2
    Registry statusSuspended

  • Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

    NCT05411081 · start 2023-03-24

    Registered record
    Registry ID
    NCT05411081
    Conditions
    Metastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
    Interventions
    Atezolizumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-03-24
    Completion
    2027-07-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
    InterventionAtezolizumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

    NCT05691478 · start 2023-03-03

    Registered record
    Registry ID
    NCT05691478
    Conditions
    High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma
    Interventions
    Bone Scan; Cabozantinib S-malate; Cisplatin; Computed Tomography; Doxorubicin Hydrochloride; Magnetic Resonance Imaging; Methotrexate; Surgical Procedure; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Suspended
    Start
    2023-03-03
    Completion
    2030-03-20
    Enrolment
    1,122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma
    InterventionBone Scan; Cabozantinib S-malate; Cisplatin; Computed Tomography +5 more
    PhasePhase 2 / Phase 3
    Registry statusSuspended

  • Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

    NCT05327738 · start 2022-12-10

    Registered record
    Registry ID
    NCT05327738
    Conditions
    BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Locally Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma
    Interventions
    Atezolizumab; Biopsy; Cabozantinib S-malate; Yttrium Y 90 Glass Microspheres
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-12-10
    Completion
    2027-12-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Locally Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma +1 more
    InterventionAtezolizumab; Biopsy; Cabozantinib S-malate; Yttrium Y 90 Glass Microspheres
    PhasePhase 2
    Registry statusWithdrawn

  • BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    NCT05136196 · start 2022-12-06

    Registered record
    Registry ID
    NCT05136196
    Conditions
    Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Melanoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Recurrent Melanoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions
    Biopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-06
    Completion
    2027-01-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 +16 more
    InterventionBiopsy Procedure; Biospecimen Collection; Cabozantinib S-malate; Computed Tomography +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

    NCT05111574 · start 2022-08-11

    Registered record
    Registry ID
    NCT05111574
    Conditions
    Anal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma; Gallbladder Melanoma; Head and Neck Mucosal Melanoma; Mucosal Melanoma; Nasopharyngeal Mucosal Melanoma; Oral Cavity Mucosal Melanoma; Penile Mucosal Melanoma; Rectal Melanoma; Recurrent Mucosal Melanoma; Sinonasal Mucosal Melanoma; Urethral Melanoma; Urinary System Mucosal Melanoma; Vaginal Melanoma; Vulvar Melanoma
    Interventions
    Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Nivolumab; Placebo Administration; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-08-11
    Completion
    2027-07-15
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Melanoma; Bladder Melanoma; Cervical Melanoma; Esophageal Melanoma +13 more
    InterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +5 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

    NCT05092958 · start 2022-06-03

    Registered record
    Registry ID
    NCT05092958
    Conditions
    Advanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis and Ureter Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8
    Interventions
    Avelumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-06-03
    Completion
    2029-07-15
    Enrolment
    654

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Bladder Urothelial Carcinoma; Advanced Renal Pelvis Urothelial Carcinoma; Advanced Ureter Urothelial Carcinoma; Advanced Urethral Urothelial Carcinoma +14 more
    InterventionAvelumab; Biospecimen Collection; Bone Scan; Cabozantinib S-malate +4 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

    NCT05092373 · start 2022-04-29

    Registered record
    Registry ID
    NCT05092373
    Conditions
    Advanced Breast Carcinoma; Advanced Endometrial Carcinoma; Advanced Fallopian Tube Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Malignant Abdominal Neoplasm; Advanced Malignant Female Reproductive System Neoplasm; Advanced Malignant Thoracic Neoplasm; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Renal Cell Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Malignant Abdominal Neoplasm; Malignant Solid Neoplasm; Metastatic Breast Carcinoma; Metastatic Endometrial Carcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Malignant Abdominal Neoplasm; Metastatic Malignant Female Reproductive System Neoplasm; Metastatic Malignant Thoracic Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Metastatic Renal Cell Car
    Interventions
    Atezolizumab; Cabozantinib S-malate; Nab-paclitaxel; Tumor Treating Fields Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-04-29
    Completion
    2026-09-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Carcinoma; Advanced Endometrial Carcinoma; Advanced Fallopian Tube Carcinoma; Advanced Hepatocellular Carcinoma +23 more
    InterventionAtezolizumab; Cabozantinib S-malate; Nab-paclitaxel; Tumor Treating Fields Therapy
    PhasePhase 1
    Registry statusRecruiting

  • Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    NCT05168618 · start 2022-03-29

    Registered record
    Registry ID
    NCT05168618
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Atezolizumab; Cabozantinib S-malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-03-29
    Completion
    2027-01
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionAtezolizumab; Cabozantinib S-malate
    PhasePhase 2
    Registry statusRecruiting

  • Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

    NCT04514484 · start 2021-11-22

    Registered record
    Registry ID
    NCT04514484
    Conditions
    Advanced Differentiated Thyroid Gland Carcinoma; Advanced Head and Neck Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Kaposi Sarcoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Carcinoma; Advanced Prostate Carcinoma; Advanced Renal Cell Carcinoma; Advanced Thyroid Gland Medullary Carcinoma; Advanced Triple-Negative Breast Carcinoma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Castration-Resistant Prostate Carcinoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; HIV Infection; Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Kaposi Sarcoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma
    Interventions
    Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-11-22
    Completion
    2027-02-06
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Differentiated Thyroid Gland Carcinoma; Advanced Head and Neck Carcinoma; Advanced Hepatocellular Carcinoma; Advanced Kaposi Sarcoma +24 more
    InterventionBiospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging +1 more
    PhasePhase 1
    Registry statusActive not recruiting

  • CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

    NCT05122546 · start 2021-11-01

    Registered record
    Registry ID
    NCT05122546
    Conditions
    Advanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
    Interventions
    Cabozantinib S-malate; Clostridium butyricum CBM 588 Probiotic Strain; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-11-01
    Completion
    2027-01-12
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Clear Cell Renal Cell Carcinoma; Advanced Papillary Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma +8 more
    InterventionCabozantinib S-malate; Clostridium butyricum CBM 588 Probiotic Strain; Nivolumab
    PhasePhase 1
    Registry statusActive not recruiting

  • Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

    NCT04878029 · start 2021-07-23

    Registered record
    Registry ID
    NCT04878029
    Conditions
    Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
    Interventions
    Cabozantinib S-malate; Enfortumab Vedotin; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-07-23
    Completion
    2028-12-21
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfiltrating Bladder Urothelial Carcinoma With Squamous Differentiation; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
    InterventionCabozantinib S-malate; Enfortumab Vedotin; Quality-of-Life Assessment; Questionnaire Administration
    PhasePhase 1
    Registry statusRecruiting

  • Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

    NCT04442581 · start 2021-04-20

    Registered record
    Registry ID
    NCT04442581
    Conditions
    Advanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma
    Interventions
    Cabozantinib S-malate; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-04-20
    Completion
    2022-03-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Hepatocellular Carcinoma; BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma
    InterventionCabozantinib S-malate; Pembrolizumab
    PhasePhase 2
    Registry statusTerminated